GLP-1 Peptide Atlas, by Delfa

CompletedPhase 4

Preoperative Condition in Giant Obese Patients

A Novel Preoperative Conditioning Therapy in Giant Obese Patients With the Combination of Liraglutide and a Leucine-Based Amino-Acid Infusion and Caloric Restriction

Lead sponsor

Sana Klinikum Offenbach

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Bariatric Surgery Candidate, Obesity / overweight

Key I/E criterion

—

Primary endpoint

•Operability

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02616003

Org study IDFF 121/2015

Timeline

Milestones

Study first posted2015-11-26estimated

Last update posted2021-03-23actual

Study start2014-04actual (month precision)

Primary completion2018-01actual (month precision)

Study completion2018-04actual (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Bariatric Surgery CandidateObesity / overweight

Eligibility

Who can enroll

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•multimorbid, super-super obese patients

Exclusion criteria

•renal insufficiency III

Endpoints (10)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

MASH / liver

Cardiometabolic biomarkers

Other clinical outcomes

Other (unclassified)

Weight & body composition

Glycemic / diabetes

Weight & body composition

1 endpoint

Secondary/protocol endpoint

Preoperative excess weight loss in %

Time frame:21 days

percent change from baseline, improvement

Glycemic / diabetes

1 endpoint

Secondary/protocol endpoint

Hg A1c in %

Time frame:21 days

descriptive, improvement

LOINC 4548-4

MASH / liver

2 endpoints

Secondary/protocol endpoint

Liver volume

Time frame:21 days

change from baseline, improvement

Secondary/protocol endpoint

Liver function

Time frame:21 days

change from baseline, improvement

Cardiometabolic biomarkers

2 endpoints

Secondary/protocol endpoint

Chronic inflammation

Time frame:21 days

hs-CRP, change

change from baseline, improvement

LOINC 30522-7

Secondary/protocol endpoint

Chronic inflammation II

Time frame:21 days

change from baseline, improvement

Other clinical outcomes

2 endpoints

Primary/protocol endpoint

Operability

Time frame:21 days

categorical status, improvement

Secondary/protocol endpoint

Pulmonary function

Time frame:21 days

change from baseline, improvement

Other (unclassified)

2 endpoints

Secondary/protocol endpoint/low confidence

Total Protein in g/l

Time frame:21 days

descriptive

Secondary/protocol endpoint/low confidence

Albumin in g/l

Time frame:21 days

descriptive

Publications (7)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Fast-track rescue weight reduction therapy to achieve rapid technical operability for emergency bariatric surgery in patients with life-threatening inoperable severe obesity - A proof of concept study.
Clinical nutrition ESPEN2022 Aug (month)PMID35871930doi:10.1016/j.clnesp.2022.05.009via clinicaltrials gov reference derived + pubmed nct search
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
The New England journal of medicine2015 Jul 2PMID26132939doi:10.1056/NEJMoa1411892via CT.gov reference
Reviewing the Effects of L-Leucine Supplementation in the Regulation of Food Intake, Energy Balance, and Glucose Homeostasis.
Nutrients2015 May 22PMID26007339doi:10.3390/nu7053914via CT.gov reference
Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight.
The Journal of clinical investigation2014 Oct (month)PMID25202976doi:10.1172/JCI78371via CT.gov reference
Glucagon-like Peptide-1 receptor signaling in the lateral parabrachial nucleus contributes to the control of food intake and motivation to feed.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2014 Aug (month)PMID24681814doi:10.1038/npp.2014.74via CT.gov reference
Impact of leucine on energy balance.
Journal of physiology and biochemistry2013 Mar (month)PMID22535285doi:10.1007/s13105-012-0170-2via CT.gov reference
Increasing dietary leucine intake reduces diet-induced obesity and improves glucose and cholesterol metabolism in mice via multimechanisms.
Diabetes2007 Jun (month)PMID17360978doi:10.2337/db07-0123via CT.gov reference

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.